مواقع ذات صلة
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
هل أنت مستخدم جديد؟ قم بالتسجيل الآن
 
دعنا نساعدك
للوصول إلى هدفك.

الدراسة الإستقصائية للمستشفيات الوطنية

Process
  • All hospitals that are contracted to the MOPH for treatment of MOPH patients in 2001will be included in the First National Hospital Survey and the main purpose is to assess all contracted hospitals against the Basic and Accreditation standards, for bench marking purposes.
  • The First National Hospital Survey will be undertaken by the OPCV Project Team under the supervision of the Ministry of Public Health (MOPH) and the Health Sector Rehabilitation Project (HSRP). The Project is financed by the World Bank.
 
Resources
  • The attached forms cover all acute hospital Departments/ Services for Basic and Accreditation standards.
  • The forms should be considered in conjunction with the relevant section of the (a) Hospital Accreditation Manual, and (b) Guidelines. Both these publications are included in the kit.
  • The forms will be used by the visiting Hospital Survey Team to assess each Department/Service of your hospital against the standards.
  • Your hospital may utilise these forms in your preparation for the survey, by photocopying as many as required for self-assessment purposes. However, in the First National Hospital Survey your self-assessment is not included as a part of the official result.
 
Survey
  • A schedule of visits by the Survey Teams is currently being compiled. It is vitally important that once the survey dates are arranged that your hospital does not alter the dates. There are some 134 hospitals involved in the survey that will take place over a 12 month period. Any hospitals reneging on the survey dates without very advanced negotiation will either go to the back of the queue or be relegated from the survey altogether. Your cooperation in regard to the scheduling is crucial to the success of the exercise.
  • For the majority of hospital surveys there will be three surveyors per team, consisting of a general hospital Administrator, a Nurse with clinical and administrative experience, and a Physician with clinical and administrative experience. There will be an extra clinical team member for hospitals over 150 beds in total.
  • For some surveys there will be an observer with the team. This will be a person from either the MOPH or the HSRP. The observer will be undergoing training as a surveyor through the OPCV so that skills can be transferred for future surveys in Lebanon. The observer will not have any executive, advisory or reporting responsibilities during his/her training period with OPCV. All aspects of confidentiality in regard to individual hospital information and results will be respected.
  • The survey team will be on site at the hospital for a varying number of days depending on hospital size in terms of total bed numbers as per official MOPH lists:
 
Hospital size On site survey days
49 beds or less One day (1)
50-99 beds Two days (2)
100-149 beds Two days (2)
150 + beds Three Days (3)
 
 
Scoring
The scoring system to be used for surveys will be as follows:
Basic standards Yes: One point
No: Zero points
Not Applicable: Excluded from calculation
Accreditation standards Yes: One point
No: Zero points
Needs improvement: 0.5 points
Not applicable: Excluded from calculation
 
  • Needs improvement.This category has been developed for the Accreditation standards so that the survey team can allot some credit where the hospital is making demonstrated progress on a particular standard. The category is not used for the Basic standards because these are lower level standards that are expected to be fully implemented
  • The Survey Team will calculate the Department/ Service results, and the overall result and advise the MOPH and your hospital at the completion of the First National Hospital Survey. All hospitals will be measured against both the Basic and the Accreditation standards
 
Results
  • The overall percentage required for the various assessments are:
% Basic % Accreditation Result Acronym
85% Basic Standards  65% + Accreditation Standards Full Accreditation Status  BFA
65% - 84% Basic Standards 65% + Accreditation Standards Partial Accreditation Status  BPA
65% + Basic Standards < 65% Accreditation Standards No Accreditation Award but passed Basic  BNA
50% - 64% Basic Standards < 65% Accreditation Standards No Accreditation award, Partial pass on Basic  PB
< 50% Basic Standards < 65% Accreditation Standards No Accreditation Award and Failed on Basic Standards NB
 
  • After the on site visit the OPCV Team will be involved in writing up the survey in the OPCV office. A detailed survey assessment report will be completed and Forworded to the MOPH and your Hospital.
  • During the First National Hospital Survey the opportunity will also be taken by the OPCV Team to recommend any changes to the Hospital Accreditation Manual and/or the processes adopted for surveys.
  • Beyond that there will be an interim period in which hospitals can prepare for actual Accreditation Assessment, based on the Survey results.
 
Further Contact
Please contact the OPCV Team Leader or the HSRP if you have any comments or queries about this Accreditation Survey Kit:
  • OPCV: Telephone 1 747 263/64
  • HSRP: Telephone 1 616 601 Mr. Roy Wakim
 
    ...
    17
التصنيف العلاجي الاسم أساسي / جنيسي التركيبة العلمية العيار الشكل الصيدلاني سعر المبيع من العموم
N06DA02 ALZEPIL G Donepezil HCl - 5mg 5mg Tablet 1,406,555 L.L
N06DA02 ARIPEZIL 5 G Donepezil HCl - 5mg 5mg Tablet, film coated 1,970,969 L.L
N06DA02 ARICEPT B Donepezil HCl - 10mg 10mg Tablet, film coated 3,776,197 L.L
N06DA02 ALZEPIL G Donepezil HCl - 10mg 10mg Tablet 1,908,256 L.L
N06DA02 ARIPEZIL 10 G Donepezil HCl - 10mg 10mg Tablet, film coated 2,292,595 L.L
N07BB03 ACAMPROSATE BIOGARAN G Acamprosate - 333mg 333mg Tablet, gastroresistant 3,641,813 L.L
N07CA01 ALVIGO G Betahistine dihydrochloride - 16mg 16mg Tablet, scored 1,204,339 L.L
P02CA03 ALBENDA G Albendazole - 100mg/5ml 400mg/20ml Suspension 129,009 L.L
P02CA03 ALBENDA G Albendazole - 200mg 200mg Tablet 116,914 L.L
P02CA03 ALBENDAZOLE-UBSA G Albendazole - 200mg 200mg Tablet 127,985 L.L
P02CA03 ANDAZOL G Albendazole - 200mg 6 Tablet, film coated 302,365 L.L
R01AC03 ALLERGODIL NASAL B Azelastine HCl - 0.14mg/dose 0.14mg/dose Spray, solution 657,139 L.L
R01AD09 AVOCOM G Mometasone furoate - 0.05% 0.05% Spray 419,279 L.L
R01AD12 AVAMYS B Fluticasone furoate - 27.5mcg/dose 27.5mcg/dose Suspension 722,987 L.L
R01AD12 AVAMYS B Fluticasone furoate - 27.5mcg/dose 27.5mcg/dose Suspension 722,987 L.L
R01BA53 AURIMEL B Phenylephrine HCl - 5mg/5ml, Sodium citrate - 325mg/5ml, Carbinoxamine maleate - 2mg/5ml, Dextromethorphan HBr - 5mg/5ml Syrup 319,963 L.L
R02A ALFA-AMYLASE BGR CONSEIL G Alpha-Amylase - 3,000U.CEIP 3,000U.CEIP Tablet, coated 290,270 L.L
R02A ALFA-AMYLASE BGR CONSEIL G Alpha-Amylase - 200U.CEIP/ml 200U.CEIP/ml Syrup 384,339 L.L
R02A ANGINOVAG G Lidocaine HCl - 100mg/100ml, Hydrocortisone acetate - 60mg/100ml, Tyrothricin - 400mg/100ml, Dequalinium chloride - 100mg/100ml, ?-Glycerrhetinic acid - 60mg/100ml Spray 651,764 L.L
R02AA20 ANGINOVA G Lidocaine HCl - 1mg, Dequalinium HCl - 0.25mg Lozenge 349,399 L.L
R03AC02 ASMALAT G Salbutamol (sulfate) - 2mg/5ml 2mg/5ml Syrup 177,899 L.L
R03AC02 ASTHALIN G Salbutamol (sulfate) - 2.5mg/2.5ml 2.5mg/2.5ml Inhalation solution 325,210 L.L
R03AK13 AEROCORT-A HFA G Salbutamol - 100mcg/dose, Beclometasone - 50mcg/dose Metered dose inhaler 541,569 L.L
R03AL01 ATROVENT COMP. HFA B Fenoterol Hydrobromide - 20mcg/actuation, Ipratropium bromide - 50mcg/actuation Inhalation aerosol metered dose 544,256 L.L
R03AL03 ANORO ELLIPTA B Vilanterol - 25mcg, Umeclidinium bromide - 62.5mcg Inhalation powder 5,367,774 L.L
R03BA02 AERONIDE G Budesonide - 200mcg 200mcg Capsule, inhalation 1,150,329 L.L
R03BA02 AERONIDE G Budesonide - 400mcg 400mcg Capsule, inhalation 2,116,552 L.L
R03BB01 ATROVENT B Ipratropium bromide - 250mcg/2ml 250mcg/2ml Inhaltion solution with nebuliser 544,256 L.L
R03BB01 ATROVENT B Ipratropium bromide - 500mcg/2ml 500mcg/2ml Inhaltion solution with nebuliser 713,580 L.L
R03BB01 ATROVENT N B Ipratropium bromide - 20mcg/actuation 20mcg/actuation Inhalation aerosol metered dose 428,686 L.L
    ...
    17
Sitemap
حقوق الطبع والنشر محفوظة ل وزارة الصحة العامة ©2025